A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 14, 2016

Primary Completion Date

February 4, 2020

Study Completion Date

February 4, 2020

Conditions
Metastatic Colorectal Cancer
Interventions
OTHER

No intervention

Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling

Trial Locations (23)

1000

Institut Jules Bordet X, Brussels

1070

Hospital Erasme, Brussels

1160

CHIREC, Auderghem

1200

Cliniques Universitaires St-Luc, Brussels

2300

AZ Turnhout Sint Elisabeth, Turnhout

2800

AZ St Maarten Campus Leopoldstr, Mechelen

2820

Imeldaziekenhuis, Bonheiden

2930

AZ KLINA, Brasschaat

3000

UZ Leuven Gasthuisberg, Leuven

3500

Jessa Zkh (Campus Salvator), Hasselt

4000

CHC MontLégia, Liège

CHU Sart-Tilman, Liège

4800

CHR de Verviers - East Belgium, Verviers

6000

Grand Hôpital de Charleroi Notre Dame, Charleroi

6110

Hôpital André Vésale, Montigny-le-Tilleul

8000

AZ Sint Jan, Bruges

8310

AZ Sint Lucas Brugge, Assebroek

8400

AZ Damiaan, Ostend

8800

AZ Delta (Campus Wilgenstraat), Roeselare

9000

AZ Maria Middelares, Ghent

9100

AZ Nikolaas (Sint Niklaas), Sint-Niklaas

9300

Onze Lieve Vrouwziekenhuis Aalst, Aalst

9600

AZ Glorieux- vzw Werken Glorieux, Ronse

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02673710 - A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab | Biotech Hunter | Biotech Hunter